Bortezomib-induced thrombotic thrombocytopaenic purpura

25Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Thrombotic thrombocytopaenic purpura (TTP) is a thrombotic microangiopathy characterised by haemolytic anaemia, schistocytes on peripheral blood smear and thrombocytopaenia that can additionally present with fever, renal insufficiency and/or neurological abnormalities. While our understanding of idiopathic TTP has significantly advanced, there are still many unanswered questions regarding the pathophysiology of secondary TTP, which can be associated with malignancy, pregnancy, HIV infection, bone marrow transplantation and exposure to certain drugs including several chemotherapeutic agents. Here we present a case of bortezomib-associated TTP. Our patient developed microangiopathic haemolytic anaemia, thrombocytopaenia and altered mental status after her ninth dose of bortezomib. The drug was subsequently discontinued and the patient underwent one session of plasma exchange with clinical improvement and recovery of her platelet counts, disappearance of schistocytes and resolution of both neurological symptoms and haemolysis in 2 days. Copyright 2012 BMJ Publishing Group. All rights reserved.

Cite

CITATION STYLE

APA

Mehta, N., Saxena, A., & Niesvizky, R. (2012). Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ Case Reports. https://doi.org/10.1136/bcr-2012-006461

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free